NON SMALL CELL LUNG CANCER NSCLC

This study tests a wearable device that sends low-intensity electric fields to tumors, combined with the immunotherapy drug pembrolizumab, in people with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if this combination helps peo…

This study tests whether adding a second immunotherapy drug to the standard drug cemiplimab works better for advanced lung cancer with high PD-L1. About 102 adults who have not had prior treatment will receive one of three combinations. The goal is to find safe doses and see if t…

This program offers early access to telisotuzumab vedotin for people with non-small cell lung cancer who have no other suitable treatments and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by regulato…

This study compares a new drug, MK-2870, to standard chemotherapy (docetaxel or pemetrexed) in 556 adults with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations or others). The goal is to see if MK-2870 can slow cancer growth and help people li…

This program provides expanded access to cemiplimab, a cancer immunotherapy, for patients with certain solid tumors like non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. It is designed for people who cannot join a clinical trial and have no…

This early-phase study tests an experimental drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body processes the drug. About 222 people with lung, colorectal, or pancreatic cancer th…

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system recognize and attack cancer cells. They are given alongside standard chemotherapy and an immune checkpoint inhibitor for people with advanced non-small cell lung cancer or …

This study tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy (cemiplimab) can shrink tumors in people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. About 60 participants will receive the combination to …

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer with a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will rece…

This early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…

This study looks at how well the drug brigatinib works in adults with a specific type of lung cancer (ALK-positive NSCLC). Researchers will track how long the cancer stays under control and how many patients respond to treatment. About 50 participants will receive brigatinib as p…

This early-stage study tests a new drug called HER3-DXd in people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. The study includes patients with certain genetic changes (EGFR or KRAS mutations) whose cancer worsened after other …

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.

This study tested whether adding the immunotherapy drugs durvalumab and tremelimumab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. About 1,200 adults whose cancer had spread and who had not received prior treatment took part. The goal…

This study tests an experimental oral drug called IMM-1-104 in people with advanced solid tumors that have RAS mutations. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 209 adults with certain cancers like pancreatic, melanoma, or lu…

This early-phase study tests an experimental drug called cofetuzumab pelidotin in about 65 adults with a specific type of advanced lung cancer (non-small cell) that has returned after standard treatments. The drug is designed to seek out and attack cancer cells that have a protei…

This study tests whether combining a targeted drug (osimertinib) with precise radiation (SABR) can help people with advanced EGFR-mutant lung cancer live longer without their disease getting worse. About 41 adults with this specific type of lung cancer will receive both treatment…

This program provides access to the drug ceritinib for people with serious ALK-positive tumors, including non-small cell lung cancer, who have no other treatment options. It is only available when a licensed doctor requests it and the patient cannot join a clinical trial. The goa…

This study tests an experimental drug called RP1, alone or with the immunotherapy nivolumab, in people with advanced solid tumors like melanoma, lung cancer, and certain skin cancers. The goal is to see if the combination is safe and can shrink tumors. About 340 adults with tumor…

This study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …

This early study tests a new treatment using a patient's own immune cells, modified to recognize and attack cancer cells with a specific KRAS G12V mutation. It includes up to 8 adults with advanced colorectal, pancreatic, or non-small cell lung cancer who have not responded to st…

This study tests whether adding olaparib to durvalumab as maintenance therapy can keep stage IV non-small cell lung cancer from progressing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy plus durvalumab will receive either th…

This study observes 404 adults in Italy with advanced non-small cell lung cancer who are receiving a combination of two immunotherapy drugs (nivolumab and ipilimumab) as their first treatment. The goal is to collect real-world data on how well the treatment works and its safety, …

This study compares two ways of collecting tissue from lung cancer patients during a bronchoscopy. One method uses a lab technician on site to quickly check if enough tissue is collected, while the other does not. The goal is to see which approach leads to more successful genetic…

This study follows 160 adults with lung cancer to see how their muscle mass, strength, and function change during cancer treatment. Researchers want to learn if these factors affect how well patients tolerate treatment, their quality of life, and overall survival. The goal is to …

This study looks at how long Chinese patients with a specific type of advanced lung cancer (ALK-positive NSCLC) stay on the drug brigatinib when it's their first treatment. Researchers will also track how well the drug controls the cancer over time. The study does not give any ne…

This study tracks 300 adults with advanced non-small cell lung cancer whose tumors have very low PD-L1 levels (below 1%). Researchers will review medical records to see how safe common first treatments are and how often side effects require extra care. The goal is to better under…

This early-phase study uses special PET scans to see where two experimental drugs (BI 765063 and BI 770371) go in the body and how much they reach tumors. It includes about 14 adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Par…